The cDNA sequences encoding the human ezrin and moesin N-ERMADs (amino acids 1–296) were amplified by PCR from clones F6 (Gould et al., 1989 (link)) and HEBA06 (a gift from Dr. Stachowitz, Gezentrum, Munich, Germany), respectively, using primers which generated EcoRI and HindIII sites at their ends. These products were then subcloned into the expression vector pQE16 (QIAGEN Inc., Chatsworth, CA). The cDNA sequence encoding residues 1-357 of ERM-binding phosphoprotein 50 (EBP50) was amplified by PCR with SphI and HindIII sites at the ends and subcloned into pQE70 (QIAGEN Inc.). Vector sequences coding for the six histidine tags were absent in all of the final constructs. To make the EBP50 COOH-terminal construct, the cDNA sequence encoding residues 241–357 was amplified by PCR using primers that created HindIII and BglII sites at the ends. This product was joined with the 0.99-kb BglI/HindIII fragment of pQE50 (QIAGEN Inc.) and the 2.42-kb BglI/BglII fragment of pQE16 in a three-arm ligation reaction to create the final His-tagged fusion construct. All recombinant sequences were determined to be free of PCR errors by nucleotide sequence analysis. Recombinant plasmids were propagated in the JM109 strain of Escherichia coli (Stratagene, La Jolla, CA).
For protein expression, plasmid constructs were transformed into the E. coli strain M15[pRep4] (QIAGEN, Inc.). Saturated overnight cultures were inoculated at 1:20 dilution in LB medium containing 100 μg/ml ampicillin and 25 μg/ml kanamycin, and grown for 90 min at 37°C. Isopropyl β-d -thiogalactopyranoside was added to 2 mM and cells were grown for an additional 180 min. Cells were harvested by centrifugation at 8,000 g for 15 min. Total bacterial lysates were prepared from cells resuspended in 1 vol of Laemmli buffer (Laemmli, 1970 (link)), boiled 2 min, and then passed through a 28-gauge needle to reduce viscosity.
To purify bacterially expressed ezrin or moesin N-ERMAD, induced cells were resuspended in 6 vol of 180 mM KH2PO4, pH 7.0, at 4°C, containing 50 μg/ml PMSF and 75 μg/ml benzamidine, lysed by sonication (Branson Ultrasonics Corp., Danbury, CT), clarified at 45,000 g for 10 min, and then loaded onto a preequilibrated hydroxyapatite column (HA–Ultragel;Pharmacia Fine Chemicals , Piscataway, NJ). The column was developed using a six-column volume linear gradient of 180–800 mM KH2PO4, and fractions were monitored by SDS-PAGE on 15% gels. Fractions rich in N-ERMAD were pooled, dialyzed against 20 mM MES, 150 mM NaCl, pH 6.7, at 4°C, centrifuged at 45,000 g for 10 min, applied to a preequilibrated S-Sepharose column (Pharmacia Fine Chemicals , Piscataway, NJ), and developed with a five-column volume linear gradient of 0.15–1.0 M NaCl. Homogenous N-ERMAD eluted at ∼490 mM NaCl.
To purify recombinant EBP50, induced bacterial lysates were prepared in TBS (50 mM Tris, 0.15 M NaCl, pH 7.4, at 4°C) in the presence of protease inhibitors, according to the method described above, and EBP50 affinity purified using N-ERMAD–coupled beads in a manner analogous to that used in the affinity binding assay. After washing the beads in TBS made up to 0.5 M NaCl, bound EBP50 was eluted with 2 M NaI, or by boiling the beads in Laemmli buffer.
The His-tagged EBP50 COOH-terminal fusion product was purified on nickel nitrilo-triacetic acid resin (QIAGEN) under denaturing conditions in 8 M urea, according to the manufacturer's protocol.
For protein expression, plasmid constructs were transformed into the E. coli strain M15[pRep4] (QIAGEN, Inc.). Saturated overnight cultures were inoculated at 1:20 dilution in LB medium containing 100 μg/ml ampicillin and 25 μg/ml kanamycin, and grown for 90 min at 37°C. Isopropyl β-
To purify bacterially expressed ezrin or moesin N-ERMAD, induced cells were resuspended in 6 vol of 180 mM KH2PO4, pH 7.0, at 4°C, containing 50 μg/ml PMSF and 75 μg/ml benzamidine, lysed by sonication (Branson Ultrasonics Corp., Danbury, CT), clarified at 45,000 g for 10 min, and then loaded onto a preequilibrated hydroxyapatite column (HA–Ultragel;
To purify recombinant EBP50, induced bacterial lysates were prepared in TBS (50 mM Tris, 0.15 M NaCl, pH 7.4, at 4°C) in the presence of protease inhibitors, according to the method described above, and EBP50 affinity purified using N-ERMAD–coupled beads in a manner analogous to that used in the affinity binding assay. After washing the beads in TBS made up to 0.5 M NaCl, bound EBP50 was eluted with 2 M NaI, or by boiling the beads in Laemmli buffer.
The His-tagged EBP50 COOH-terminal fusion product was purified on nickel nitrilo-triacetic acid resin (QIAGEN) under denaturing conditions in 8 M urea, according to the manufacturer's protocol.